Roche Q1 Sales Rise 6% at CER, 9% in USD
Roche reported first-quarter group sales growth of 6% at constant exchange rates and a 9% increase in USD, despite a 5% decline in Swiss franc terms, driven by strong demand for medicines such as Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus. The company reaffirmed its full-year guidance after Q1 results.
1. Q1 Sales Performance
Roche posted group sales growth of 6% at constant exchange rates in the first quarter, with sales declining 5% in Swiss francs but rising 9% in U.S. dollar terms.
2. Division and Product Drivers
The Pharmaceuticals Division achieved 7% CER growth, with top contributors including Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus, reflecting strong demand across severe disease treatments.
3. Foreign Exchange Impacts
The Swiss franc’s appreciation led to a reported 5% sales decline, while a weaker U.S. dollar conversion boosted reported results by 9%, underscoring currency volatility’s impact on financial reporting.
4. Full-Year Guidance Confirmation
Following the robust first-quarter performance, Roche management reaffirmed its full-year guidance, signaling confidence in sustained growth across medicines and diagnostics.